Monitoring of human papillomavirus vaccination.

Research output: Contribution to journalArticle

Standard

Monitoring of human papillomavirus vaccination. / Dillner, Joakim; Arbyn, M; Unger, E; Dillner, Lena.

In: Clinical and Experimental Immunology, Vol. Dec, 2011, p. 17-25.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Dillner, Joakim ; Arbyn, M ; Unger, E ; Dillner, Lena. / Monitoring of human papillomavirus vaccination. In: Clinical and Experimental Immunology. 2011 ; Vol. Dec. pp. 17-25.

RIS

TY - JOUR

T1 - Monitoring of human papillomavirus vaccination.

AU - Dillner, Joakim

AU - Arbyn, M

AU - Unger, E

AU - Dillner, Lena

PY - 2011

Y1 - 2011

N2 - Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.

AB - Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.

U2 - 10.1111/j.1365-2249.2010.04268.x

DO - 10.1111/j.1365-2249.2010.04268.x

M3 - Article

VL - Dec

SP - 17

EP - 25

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

ER -